Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Nectar Lifesciences Limited (NSE: NECLIFE), ISIN INE023H01027 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
NECLIFE last traded at ₹11.04 (+1.75%), with a 52-week range of ₹9.20 to ₹22.49 (as of 23 Sep 2026).
Shareholding as of Jun 2026: promoters 51.84%, FIIs 0.50%, DIIs 3.74%, mutual funds 0.00%.
EquiSense Score (ECS): 22/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.